Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 12/20 | 0.46 |
| ▸ | OXTR | P30559 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.37 |
| ▸ | CDK9 | P50750 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1307032 | 0.87 | HPGD (0.46) | HPGDOXTRALDH1A1MEN1GAA | |
| SCHEMBL3809041 | 0.83 | F2 (0.42) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL28773746 | 0.83 | HPGD (0.43) | HPGDOXTRALDH1A1MEN1GAA | |
| SCHEMBL1308827 | 0.81 | HPGD (0.41) | HPGDOXTRALDH1A1MEN1GAA | |
| SCHEMBL1306185 | 0.80 | HPGD (0.42) | HPGDOXTRALDH1A1MEN1GAA | |
| SCHEMBL1306732 | 0.79 | ALDH1A1 (0.45) | HPGDOXTRALDH1A1MEN1GAA | |
| SCHEMBL1307651 | 0.79 | HPGD (0.41) | HPGDALDH1A1MEN1GAAKMT2A | |
| SCHEMBL1308086 | 0.79 | HPGD (0.41) | HPGDOXTRALDH1A1MEN1GAA | |
| SCHEMBL1307673 | 0.79 | HPGD (0.41) | HPGDOXTRALDH1A1MEN1GAA | |
| SCHEMBL1307618 | 0.78 | HSD11B1 (0.49) | HPGDOXTRALDH1A1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-12-22 | — | — | US | disclosed |
| US-8053431-B2 | Pharmaceutical use of substituted amides | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-11-08 | — | — | US | disclosed |
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HIGH POINT PHARMACEUTICALS, LLC | 2009-05-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118259-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, CYP11B1, HSD11B2 | HPGD 27/4885OXTR 4246/4885ALDH1A1 187/4885 |
| US-20110312949-A1 | PHARMACEUTICAL USE OF SUBSTITUTED AMIDES | HSD11B1, HSD3B1, HSD11B2 | HPGD 28/4885OXTR 4160/4885ALDH1A1 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.